Table 1 Characteristics of studies and patients
Studies | Geographical origin | No. of patients | No. of dialysis recipients | History of Cirrhosis (%) | mean/median baseline RNA | Genotype | SOF-based regimen | Dose of SOF | SVR12/24 (PP) | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|
Aggarwal (2017) [19] | USA | 14 | 14 | 20% (F3,F4) | 8,375,588.6 IU/ML | GT1–60%, GT2–6.7%, GT3–20%, GT4–13.3% | SOF + SMV, SOF + RBV, SOF/LDV ± RBV, SOF + PR, SOF + DCV 12–24 W | 200 mg QD | 92.8% 13/14 | 4 |
Akhil (2018) [26] | India | 22 | 22 | NA | 2,642,495 IU/ML | GT1–63.63%, GT3–27.27%, GT4–9% | SOF + RBV 12 W | 400 mg QD | 80% 16/20 | 4 |
Beinhardt (2016) [27] | Austria | 10 | 10 | 40% (30% decompensation) | 6.1 ± 0.8 log IU/ML | GT1a-20%, GT1b-40%, GT3a-20%, GT4–20% | SOF + PR, SOF + SMV, SOF + DCV, SOF + RBV 12–24 W | 400 mg QD | 90% 9/10 | 4 |
Bera (2017) [20] | India | 25 | 25 | 20% | 6.4 ± 0.57 log IU/ML | GT3–72%, GT1–24%, GT4–4% | SOF + DCV 12–24 W | 400 mg/48 h | 100% 16/16 | 4 |
Bhamidimarri (2015) [31] | USA | 15 | 12 | 60% | 9.7 × 106 IU/ML | GT1a-67%, GT1b-33% | SOF + SMV 12–24 W | 200 mg QD or 400 mg/48 h | 87% 13/15 | 4 |
Butt (2108) [45] | USA | 137 | NA | NA | NA | NA | SOF/LDV ± RBV 12–16 W | 400 mg QD | 95% 103/108 | 3 |
Choudhary (2017) [21] | India | 16 | 16 | 12.50% | 7 (5–8) log IU/ML | GT1–69%, GT3–25%, GT-6% | SOF + PR, SOF + DCV ± RBV12 W | 400 mg/48 h | 80% 8/10 | 4 |
Desnoyer (2016) [32] | France | 12 | 12 | 83% | 6.59 (6.13–6.86) log IU/ML | GT1–92% GT2–8% | SOF + SMV, SOF + DCV, SOF/LDV, SOF + RBV 12–24 W | 400 mg QD or 400 mg TIW | 83% 10/12 | 5 |
Dumortier (2017) [18] | France | 50 | 35 | 54% | 2,603,063 IU/ML | GT1–56%, GT2–12%, GT3–10%, GT4–18%, GT5–4% | SOF + RBV, SOF + PR, SOF + DCV ± RBV, SOF + SMV ± RBV 12–24 W | 400 mg QD or 400 mg/48 h or 400 mg TIW | 91% 43/47 | 5 |
Taneja (2018) [22] | India | 65 | 54 | 32.3%(9% decompensation) | 1.65 × 106 (1.2 × 103–1.73 × 108) IU/ML | GT1–65%; GT2–1%, GT3–34% | SOF + DCV 12- 24w | 200 mg QD | 100% 65/65 | 5 |
Goel (2018) [23] | India | 41 | 31 | 12% | 5.9 (4.12–9.9) log IU/ML | GT3–54%, GT1–42%, GT4–5% | SOF + DCV 12–24 W | 200 mg QD | 100% 36/36 | 4 |
Yingli (2017) [24] | China | 33 | 33 | NA | 1.7–7.8 log IU/ML | GT1b-21%, GT2a-73%, GT2a + 1b-6% | SOF + DCV | 200 mg QD | 100% 33/33 | 4 |
Lawitz (2017) [33] | USA and New Zealand | 18 | 0 | 11% | NA | GT1a-78%, GT1b-22% | SOF/LDV 12 W | 400 mg QD | 100% 18/18 | 4 |
Manoj (2018) [28] | India | 64 | 11 | NA | NA | NA | SOF + RBV, SOF/LDV, SOF + DCV 12–24 W | 400 mg QD | 100% 64/64 | 5 |
Mehta (2018) [46] | India | 38 | 38 | NA | 5.75 (5.05–6.36) log IU/ML | GT1a-42%, GT1b-58% | SOF + DCV, SOF/LDV 12 W | 400 mg QD or 400 mg/48 h | 86.8% 33/38 | 5 |
Nazario (2017) [29] | USA | 41 | 38 | 49% | NA | GT1a-66%; GT2–2%, GT3–2% | SOF + SMV, SOF/LDV, SOF + DCV 12–24 W | 400 mg QD | 100% 41/41 | 3 |
Saab (2017) [30] | USA | 12 | 12 | NA | 30,499,500 ± 29,655,754 IU/ML | GT1a-42%, GT1b-25%, GT2–17%, GT1–17% | SOF + RBV, SOF/LDV ± RBV | 400 mg QD | 70% 7/10 | 4 |
Saxena (2015) [47] | USA | 18 | 5 | 75% | NA | NA | SOF + PR, SOF + RBV, SOF + SMV ± RBV | 400 mg QD | 85% 11/13 | 5 |
Singh (2017) [34] | USA | 36 | 30 | 27.8% (16.7% decompensation) | 9.9 × 105 IU/ML | G1–72%, G3–22%, G4–5% | SOF/LDV, SOF + DCV 12 W–24 W | 400 mg QD | 97.2% 35/36 | 4 |
Surendra (2018) [25] | India | 21 | 21 | 0 | NA (63% > 800,000 IU/ML) | GT1a-63%, GT1b-37% | SOF/LDV 12 W | 400 mg/48 h | 100% 19/19 | 5 |
Cox-North (2017) [35] | USA | 29 | NA | 44%(14% decompensation) | NA | GT1–72%, GT2–7%, GT3–17% GT6–4% | SOF/LDV ± RBV, SOF + DCV ± RBV, 8-24 W | 400 mg QD | 100% 28/28 | 4 |